Zura Bio Q2 net loss widens to $26.3 million as R&D spending rises
Zura Bio reported a second-quarter 2026 net loss of $26.3 million, or $0.21 per share, up from $16.0 million, or $0.17 per share, a year earlier. Research and development expenses rose to $20.7 million from $8.7 million, which the company attributed to its Phase 2 tibulizumab programs, and it reported $205.1 million in cash as of June 30, 2026, which it expects to fund planned operations through at least the end of 2028.
Key points
- Net loss of $26.3 million ($0.21 per share) for Q2 2026, versus $16.0 million ($0.17 per share) in Q2 2025
- R&D expenses of $20.7 million versus $8.7 million a year earlier; G&A expenses fell to $8.6 million from $9.4 million
- Cash and cash equivalents of $205.1 million as of June 30, 2026, with runway through at least the end of 2028
- TibuSHIELD (247 participants) topline data expected Q4 2026; TibuSURE (91 participants) expected H1 2027; PMR Phase 2 planned by year-end 2026
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.